Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kaken to Codevelop TWOCELLS’ Cell Therapy in Japan
June 3, 2025
- Taiho Out-Licenses LSD1 Inhibitor to Yokohama Upstart
June 3, 2025
- Nxera-Lilly Collab Hits Key Milestone, Triggers Undisclosed Payment
June 3, 2025
- Enhertu Extends Survival as 2nd-Line Gastric Cancer Therapy
June 3, 2025
- Kura/Kyowa Kirin’s AML Drug Accepted for US FDA Review
June 3, 2025
- Fuso Sets Up 8 Billion Yen Credit Line after Remitch Ruling
June 3, 2025
- Bayer Files Low-Dose MRI Contrast Agent Gadoquatrane in Japan
June 3, 2025
- Servier Launches Tibsovo for IDH1-Mutated AML in Japan
June 3, 2025
- Scemblix’s 1st Line Nod Will Take CML Therapy to New Stage: Professor
June 2, 2025
- Shionogi’s OIC Med Naldemedine Accepted for Review in China
June 2, 2025
- Astellas Nabs Rights to China Firm’s CLDN18.2 ADC
June 2, 2025
- Daiichi/Merck Pull HER3-DXd Filing for NSCLC in US
June 2, 2025
- Novo Pairs Up with Sumitomo on Ozempic Promotion in Japan
June 2, 2025
- Taking on Solid Tumors - 3: J&J to Soon Have 3 Bispecifics in Japan as Rybrevant Gathers Pace
May 30, 2025
- Shingles Heavily Pitched for GPs as It Enters NIP: Intage April Data
May 30, 2025
- Eisai Wins Lenvima Patent Suit in US, Barring Generic to 2036
May 30, 2025
- Bimzelx Now Available as Single-Injection Option: UCB Japan
May 30, 2025
- Mitsubishi Re-Files NeuroDerm’s Parkinson’s Drug in US
May 30, 2025
- Towa, Sawai Log Two-Digit Growth in Operating Profit, but Industry Sees Divide: Tally
May 30, 2025
- Taking on Solid Tumors - 2: Chugai Poised to Break through Solid Cancer “Wall” with Trispecific Antibodies
May 29, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…